Cargando…
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout. Renal excretion is the major route of uric acid elimination, but th...
Autores principales: | Pierzynowska, Kateryna, Deshpande, Aditi, Mosiichuk, Nadiia, Terkeltaub, Robert, Szczurek, Paulina, Salido, Eduardo, Pierzynowski, Stefan, Grujic, Danica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732547/ https://www.ncbi.nlm.nih.gov/pubmed/33330529 http://dx.doi.org/10.3389/fmed.2020.569215 |
Ejemplares similares
-
Oral uricase eliminates blood uric acid in the hyperuricemic pig model
por: Szczurek, Paulina, et al.
Publicado: (2017) -
ALLN-177, oral enzyme therapy for hyperoxaluria
por: Lingeman, James E., et al.
Publicado: (2019) -
Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016) -
Difference in Performance of EPI Pigs Fed Either Lipase-Predigested or Creon®-Supplemented Semielemental Diet
por: Pierzynowski, Stefan G., et al.
Publicado: (2021) -
Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)